Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of rifaximin 600
mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy
subjects to prevent travelers' diarrhea (TD) from all causes.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.